Lilly reinvests tirzepatide windfall into a generational acquisition and innovation run
juanbenet · x · 2026-11-17
Cremieux argues Lilly is on a generational innovation and acquisition run across every domain, actually reinvesting the massive profits from tirzepatide into owning the future of pharma. Juan Benet calls it long-term rational action from big pharma.
More from Venture
- RightNow launches inference API, claims 14x NVIDIA performance via GPU kernels — ycombinator · 2026-11-17
- Healthcare AI spend hits $3.7B, drug discovery AI surges 23x: Menlo Ventures report — mmurph · 2026-11-17
- August raises $12M from Accel and Peak XV as its AI spends 24,286 minutes on hold booking doctor visits — anthara_ai · 2026-11-17
- Side-Hustle Idea: AI Pipeline Turns Weekend Restaurant Footage into UGC Shorts — Setting-Sonne · 2026-11-17
- Europe leads in image, audio, video and app generation — but its AI companies find customers stateside — nathanbenaich · 2026-11-17
- Solo founder loses tens of thousands to token fraud, shares her full counter-fraud playbook — annetgriffin · 2026-11-17